Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells
LBH589 inhibits cell growth and drives osteoblast differentiation of U2OS human osteosarcoma cells. (a) Survival curve of human osteosarcoma cell lines treated with increasing concentrations of LBH589. Data represent means ± SEM of quadruplicates. (b) Cell viability of U2OS cells treated with increasing concentrations of LBH589. Data represent means ± SEM of quadruplicates and dotted line = starting cell number. (c) Western blot analysis of U2OS cells with increasing concentrations of LBH589 for 24 hours. (d) Analysis of cell morphology, mineralized extracellular matrix deposition, and cellular senescence in U2OS cells treated for 21 days in 15 nM LBH589 by phase contrast microscopy, Alizarin red staining, and β-galactosidase staining, respectively. Scale bar = 500 μm. (e) Soft agar clonogenicity assay of U2OS and SJSA human osteosarcoma cells pretreated with 15 nM LBH589 for 21 days. Mean ± SEM, *, and **.